A Phase 4 interventional study of Carbetocin in Postpartum Hemorrhage and Grand Multiparity, sponsored by Dr. Lutfi Kirdar Kartal Training and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Dr. Lutfi Kirdar Kartal Training and Research Hospital · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Postpartum Hemorrhage with a site in Turkey — 4 open to participants now, 5 under way, none of them phase 3. Postpartum Hemorrhage · Turkey.
Among the 45 studies in Postpartum Hemorrhage with a site in Turkey, this one is the 15th largest by enrollment of the 35 interventional ones that give a count, is one of 7 that started in 2025, is one of 5 in phase 4, and was the 44th registered.
471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.
Browse Postpartum Hemorrhage studies →4 of the 45 studies in Postpartum Hemorrhage with a site in Turkey are open now. Recruiting first, the newest first:
Mehmet Kırıköz · Sites in Turkey
Ages 24+ · Healthy volunteers
Saglik Bilimleri Universitesi Gulhane Tip Fakultesi · Sites in Turkey
Ages 18–35 · Women only · Healthy volunteers
Bagcilar Training and Research Hospital · Sites in Turkey
Ages 18–45 · Women only · Healthy volunteers
Cukurova University · Sites in Turkey
Ages 17–25 · Women only · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 172 is above the median of 148 across 362 interventional studies indexed under Postpartum Hemorrhage.
Median enrollment 150 across the 35 interventional studies, 88 across the 10 observational. Of the 34 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 45 has an industry lead sponsor. The 10 most frequent:
Dr. Lutfi Kirdar Kartal Training and Research Hospital is the lead sponsor of 79 studies on the registry; 9 are open to participants now.
Dr. Lutfi Kirdar Kartal Training and Research Hospital has 1 study filed under Postpartum Hemorrhage — fewer than ten, so there is no comparison to draw.
1 of the studies in Postpartum Hemorrhage with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07943052Bagcilar Training and Research HospitalIntrauterine Misoprostol in Cesarean Delivery: Effect on Postpartum Hemorrhage | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 45 studies in Postpartum Hemorrhage with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled trial compared two timings of the same prophylactic carbetocin dose in grand multiparous women (five or more previous deliveries) undergoing vaginal delivery. Women received 100 µg intravenous carbetocin either immediately after delivery of the anterior shoulder (before placental delivery) or immediately after complete placental expulsion (after placental delivery). The main question was whether earlier administration reduces postpartum hemorrhage, and whether it affects placental delivery, including the need for manual removal of the placenta.
Postpartum hemorrhage (PPH) is a leading cause of maternal morbidity, and uterotonic prophylaxis is central to its prevention. A previous randomized trial in low-risk primiparous women (NCT06776926) showed that pre-placental carbetocin reduced PPH but increased manual placental removal. This single-center, double-blind trial evaluated the same comparison in grand multiparous women with uncomplicated singleton term pregnancies and spontaneous labor.
Allocation was performed by computer-generated simple randomization. A dedicated research midwife not involved in clinical care opened the allocation envelope and prepared and administered the study drug through a peripheral intravenous cannula away from the operative field; participants and the delivering obstetrician were unaware of allocation. Carbetocin (Pabal, Ferring) was given as a single 100 µg (1 mL) intravenous bolus over 1 minute.
Blood loss was measured quantitatively using calibrated under-buttocks collection drapes and gravimetric weighing. Manual removal of the placenta was performed if spontaneous placental delivery had not occurred within 30 minutes after birth.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100 mcg carbetocin administered as an intravenous bolus over 1 minute immediately after delivery of the anterior shoulder, before placental delivery.
Drug: Carbetocin
100 mcg carbetocin administered as an intravenous bolus over 1 minute immediately after complete placental expulsion.
Drug: Carbetocin
Single 100 mcg (1 mL) intravenous bolus of carbetocin administered over 1 minute through a peripheral intravenous cannula. Timing of administration differed between arms: immediately after delivery of the anterior shoulder (pre-placental) or immediately after complete placental expulsion (post-placental).
Also known as: Pabal
Incidence of Postpartum Hemorrhage
Proportion of participants with quantitatively measured blood loss of 500 mL or more, assessed using calibrated under-buttocks collection drapes supplemented by gravimetric weighing.
Time frame: From delivery of the infant up to 2 hours after delivery
Total Quantitative Blood Loss
Total peripartum blood loss in milliliters, measured quantitatively using calibrated under-buttocks collection drapes supplemented by gravimetric weighing.
Time frame: From delivery of the infant up to 2 hours after delivery
Incidence of Severe Postpartum Hemorrhage
Proportion of participants with quantitatively measured blood loss of 1000 mL or more.
Time frame: From delivery of the infant up to 2 hours after delivery
Use of Additional Uterotonic Agents
Proportion of participants requiring additional uterotonic agents (methylergonovine and/or misoprostol).
Time frame: Within 24 hours after delivery
Manual Removal of the Placenta
Proportion of participants requiring manual removal of the placenta, performed if spontaneous placental delivery had not occurred within 30 minutes after birth.
Time frame: From birth of the infant until placental delivery, assessed up to 60 minutes after birth
Duration of the Third Stage of Labor
Time in minutes from birth of the infant to complete placental expulsion.
Time frame: From birth of the infant until complete placental expulsion, assessed up to 60 minutes after birth
Transfusion
Proportion of participants receiving blood transfusion.
Time frame: Within 24 hours after delivery
Additional Surgical Interventions for Postpartum Hemorrhage
Proportion of participants requiring additional interventions for postpartum hemorrhage, including intrauterine balloon tamponade, uterine compression sutures, arterial ligation, or hysterectomy.
Time frame: Within 24 hours after delivery
Antibiotic Administration
Proportion of participants receiving protocol-driven prophylactic antibiotic administration.
Time frame: Within 24 hours after delivery
Maternal Adverse Events
Proportion of participants experiencing adverse events, including nausea, vomiting, dizziness, shivering, headache, dyspnea, flushing, and tachycardia.
Time frame: Within 24 hours after delivery
Change in Hemoglobin
Absolute change in hemoglobin (g/dL) from the predelivery value to 24 hours after delivery.
Time frame: Predelivery (baseline) and 24 hours after delivery
Change in Hematocrit
Absolute change in hematocrit (percentage points) from the predelivery value to 24 hours after delivery.
Time frame: Predelivery (baseline) and 24 hours after delivery
Plan to share: Yes — De-identified individual participant data underlying the results reported in the publication will be available from the corresponding author upon reasonable request.
Time frame: Beginning with publication of the results, with no planned end date.
Access criteria: Data will be shared with qualified researchers upon reasonable request to the corresponding author.
Ran from Jan 2025 to primary completion in Feb 2025, 1 month.
Of 28 non-industry phase 4 interventional studies under Postpartum Hemorrhage, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 1 month is below that.
Counting every sponsor, half of 29 studies reached it within 12 months; a quarter within 10 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dr. Lutfi Kirdar Kartal Training and Research Hospital